Patent Theme
Advanced Genomic Sequence Analysis
Computational techniques and algorithms for processing, aligning, and interpreting raw biological sequence data (DNA, RNA, protein), including identifying genetic variations, classifying organisms, or predicting sequence attributes.
4,322 US filings from 1,181 companies since 2023 · 2023: 1,091 · 2024: 1,390 · 2025: 1,287 · 2026 YTD: 554
Bioinformatics
Top companies
Ranked by filings in this theme since 2023. 2026 is partial.
| # | Company | Since 2023 | 2023 | 2024 | 2025 | 2026 YTD | YoY |
|---|
| 1 | Illumina, Inc. | 272 | 64 | 82 | 89 | 37 | +8.5% |
| 2 | 10x Genomics, Inc. | 193 | 38 | 64 | 74 | 17 | +15.6% |
| 3 | LIFE TECHNOLOGIES CORPORATION | 103 | 30 | 36 | 33 | 4 | -8.3% |
| 4 | Guardant Health, Inc. | 87 | 17 | 29 | 28 | 13 | -3.4% |
| 5 | Singular Genomics Systems, Inc. | 81 | 26 | 31 | 16 | 8 | -48.4% |
| 6 | Illumina Cambridge Limited | 74 | 40 | 18 | 9 | 7 | -50.0% |
| 7 | President and Fellows of Harvard College | 62 | 17 | 17 | 18 | 10 | +5.9% |
| 8 | Ultima Genomics, Inc. | 56 | 12 | 19 | 16 | 9 | -15.8% |
| 9 | Roche Sequencing Solutions, Inc. | 55 | 16 | 20 | 15 | 4 | -25.0% |
| 10 | The Regents of the University of California | 52 | 10 | 17 | 18 | 7 | +5.9% |
| 11 | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 46 | 14 | 19 | 8 | 5 | -57.9% |
| 12 | 23andMe, Inc. | 43 | 15 | 14 | 14 | · | 0.0% |
| 13 | Natera, Inc. | 42 | 4 | 13 | 15 | 10 | +15.4% |
| 14 | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 41 | 16 | 14 | 7 | 4 | -50.0% |
| 15 | The Board of Trustees of the Leland Stanford Junior University | 41 | 10 | 15 | 9 | 7 | -40.0% |
| 16 | Oxford Nanopore Technologies PLC | 39 | 6 | 8 | 16 | 9 | +100.0% |
| 17 | The Broad Institute, Inc. | 38 | 10 | 11 | 9 | 8 | -18.2% |
| 18 | The Johns Hopkins University | 37 | 3 | 11 | 16 | 7 | +45.5% |
| 19 | SEQUENOM, INC. | 37 | 7 | 15 | 13 | 2 | -13.3% |
| 20 | Microsoft Technology Licensing, LLC | 36 | 11 | 9 | 15 | 1 | +66.7% |
| 21 | NCAN Genomics, Inc. | 36 | 1 | 13 | 16 | 6 | +23.1% |
| 22 | Bio-Rad Laboratories, Inc. | 35 | 7 | 14 | 5 | 9 | -64.3% |
| 23 | University of Washington through its Center for Commercialization | 34 | 12 | 15 | 5 | 2 | -66.7% |
| 24 | Foundation Medicine, Inc. | 33 | 3 | 8 | 6 | 16 | -25.0% |
| 25 | Element Biosciences, Inc. | 32 | 9 | 7 | 10 | 6 | +42.9% |